SB

Executive Dashboard

MariTide (obesity) launch — real-time commercial pulse, AI-authored insights and risk radar.

Launch Readiness

82
Overall
Manufacturing94
Regulatory96
Market Access74
Field Readiness71
Medical Affairs88
Digital / DTC85
Patient Support78

Eligible Patients

26.4M
+3.2%Adults, BMI≥30, diagnosed

Treatable

8.1M
+4.8%Insured + affordable

Patients on MariTide

134,220
+12.4%+14,918 W/W

Revenue (Q3 F'26)

$1.28B
+9.6%vs plan +6.1%

Market Share

5.2%
+0.7%of GLP-1 obesity

HCP Coverage

61%
-1.4%of target physicians

Consumer Conversion

19.8%
+2.1%Eligibility → Rx

Adherence Rate

74%
+1.9%90-day MPR

US Opportunity Map

Composite opportunity score

Darker = higher
AK
ME
VT
NH
WA
ID
MT
ND
MN
IL
WI
MI
NY
MA
OR
UT
WY
SD
IA
IN
OH
PA
NJ
CT
RI
CA
NV
CO
NE
MO
KY
WV
VA
MD
DE
AZ
NM
KS
AR
TN
NC
SC
DC
OK
LA
MS
AL
GA
HI
TX
FL

Volume & Revenue Trajectory

TRx / NRx — 24 mo history + 24 mo forecast (Base)

Live
AI Insights
Generated · just now
  • high

    Texas + Florida show high obesity prevalence but bottom-quartile HCP coverage. Redirect 6 field FTEs to unlock ~$41M ARR.

  • medium

    Consumer copay burden above $145/mo is driving 34% of discontinuations. Expanding the affordability program cuts churn 6.2pts.

  • medium

    Zepbound share gains are concentrated in commercial payers; MariTide's efficacy edge is underused in payer detailing.

  • low

    Digital engagement is 22% below plan in Midwest. A programmatic Search + Social lift closes 60% of the gap in 8 weeks.

Risk Alerts
4 active
  • CriticalMarket Access

    Payer reject rate in CA rose to 18%

  • HighAnalytics

    Forecast accuracy dropped to 91% in TX

  • MediumSales Ops

    Field vacancy > 30 days in Region S-3

  • MediumMarketing

    Competitor DTC spend +42% W/W

Launch Timeline

18-month view
Pre-approval Prep
FDA Approval
Payer Contracting
HCP Detailing
DTC Wave 1
Patient Support Ramp
DTC Wave 2
Competitor Updates
  • Zepbound · 2h ago
    Launched new savings card capped at $25/mo for commercial patients.
  • Wegovy · 6h ago
    Peer-reviewed CV outcomes study published in NEJM.
  • Roche · 1d ago
    Phase 3 readout for oral GLP-1 positive; 17% weight loss at 52 weeks.
  • Ozempic · 2d ago
    Continued shortage messaging on payer portals.